08:00 , Dec 10, 2012 |  BC Week In Review  |  Clinical News

Cotara regulatory update

Peregrine said it reached an agreement with FDA on the design of a single Phase III trial comparing 2 doses of Cotara in up to 300 patients with recurrent glioblastoma multiforme (GBM). The company said...
07:00 , Jun 6, 2011 |  BC Week In Review  |  Clinical News

Cotara: Additional Phase II data

Additional data from an open-label, U.S. and Indian Phase II trial in 41 GBM patients at first relapse showed that a single 25-hour interstitial infusion of 2.5 mCi/cc Cotara led to an interim median OS...
23:33 , Jun 3, 2011 |  BC Extra  |  Clinical News

Peregrine reports Cotara data

Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) reported additional data from a Phase II trial in 41 glioblastoma multiforme (GBM) patients at first relapse showing that a single 25-hour interstitial infusion of Cotara led to an interim median...
08:00 , Jan 3, 2011 |  BC Week In Review  |  Clinical News

Cotara: Completed Phase II enrollment

Peregrine completed enrollment of 40 GBM patients at first relapse in an open-label, U.S. and Indian Phase II trial evaluating a single 25-hour interstitial infusion of Cotara. Cotara has Orphan Drug and Fast Track designations...
07:00 , Oct 25, 2010 |  BC Week In Review  |  Clinical News

Cotara: Interim Phase II data

Interim data from 14 evaluable patients in an ongoing, open-label, U.S. and Indian Phase II trial showed that a single, 25-hour intratumoral infusion of Cotara at first relapse resulted in a median OS of 86...
07:00 , Jun 7, 2010 |  BC Week In Review  |  Clinical News

Cotara: Phase I data

An open-label, U.S. Phase I trial in 10 patients showed that 1.5, 2 and 2.5 mCi/cm 3 Cotara administered interstitially via convection-enhanced delivery was well tolerated. There was 1 DLT of brain edema at 2.5...
07:00 , May 17, 2010 |  BC Week In Review  |  Company News

Peregrine, Stason Pharmaceuticals Inc. deal

Peregrine granted Stason exclusive rights to develop and commercialize its tumor necrosis therapy (TNT) technologies in certain Asia-Pacific Economic Cooperation (APEC) countries. The deal includes exclusive rights to Cotara, an Iodine 131 radiolabelled chimeric...
08:00 , Dec 7, 2009 |  BC Week In Review  |  Clinical News

Cotara: Completed Phase I enrollment

Peregrine completed enrollment of 12 patients in the open-label, U.S. Phase I trial evaluating 1.5, 2.0 and 2.5 mCi/cc Cotara administered interstitially via convection-enhanced delivery. Peregrine Pharmaceuticals Inc. (NASDAQ:PPHMD), Tustin, Calif.   Product: Cotara (...
07:00 , Sep 7, 2009 |  BC Week In Review  |  Clinical News

Cotara: Phase II data

Interim data from 10 evaluable patients in an open-label, Indian Phase II trial showed that a single intratumoral infusion of Cotara at first relapse resulted in a median recurrence-free survival of 33 weeks and median...
07:00 , Jun 9, 2008 |  BC Week In Review  |  Clinical News

Cotara: Phase I data

Data from 3 evaluable patients in an open-label, U.S. Phase I trial showed that the concentration of Cotara in brain tumors was >100-fold higher than in other organs after interstitial dosing. All patients in the...